ANTICARIOGENIC USE OF 3,6-ANHYDRO-L-GALACTOSE
The invention relates to oral inhibits the growth of bacteria, acid that inhibits production of 3, 6 - anhydro - L - use of galactose clause decayed tooth receptor antagonistic activity are disclosed. Finding a person who is one of the main cause dental caries dental oral disease humanity has sugar sweetener stored in a memory according to an incidence increases. Main acnes mu the [su[su] germ which burns dental caries ( For the following studies and corrosion current mu in the [su[su] germ which burns Imipenem-resistant material permits sugar clause decayed tooth although as long as natural as sweeteners antidepressant effect results in a database per study weak natural xylitol are disclosed. In the case of xylitol mu the [su[su] germ which burns xylitol is isolated pos to the gun blood base [pu[pu] it comes it buys xylitol pos the pot lance ladle sacrifice system (phosphoenolpyruvate-a xylitol phosphotrasferase system, PEP-a xylitol PTS) - 5 - xylitol by phosphoric acid activation of form. This the enzyme to do activity and are therefore not longer metabolic energy not produce extracellular form of xylitol again exit the transmitted via circuit board layer and consume acids inhibit bacterial growth to be coated. The concentration of 10 g/L mu the [su[su] germ which burns only xylitol may be inhibiting the growth culture media containing xylitol as well as by a spring that is not interrupted by the resistant strain of the xylitol growth study result formed disapproval (Trahan L The, resistant strain of low concentration can be effectively inhibit the growth of oral bacteria even command data in a database development clause decayed tooth proposal are disclosed. The aim of the invention is oral bacterial growth inhibition activity comprising galactose - L - 3, 6 - anhydro acid generation activity clause decayed tooth composition active ingredient are disclosed. In order to attain the object, the present invention relates to a method for preventing or treating diseases galactose - L - 3, 6 - anhydro oral care compositions. Also, the invention relates to preparing a pharmaceutical composition for the prevention or treatment of oral cavity diseases for 3, 6 - anhydro - L - galactose of uses. The invention also relates to a pharmaceutical composition for the prevention or treatment of oral administering to a subject a method of preventing or treating oral diseases. The invention also relates to a galactose - L - 3, 6 - anhydro oral diseases for treatment or prevention of an oral compositions. The invention also relates to a food for preventing or ameliorating diseases galactose - L - 3, 6 - anhydro oral care compositions. The 3, 6 - anhydro - L - galactose can be represented by formula 1: [Formula 1] The 3, 6 - anhydro - L - a galactose, (Pretreated) which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase enzymes or mixture, Which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - resolution direct is sequentially obtained by the reaction Neo with baby bio [su[su] hydrolase obtained by separation and purification reaction-product can be a. The pretreatment temperature in the range of 40 to 150 °C agarose and weak acid reacting 6 be a time 5 minutes. The temperature in the range of 20 to 40 °C the of enzymatic reactions in which 30 minutes 7 be a liver. The galactose - L - 3, 6 - anhydro inhibit growth of oral bacteria, oral bacteria carbon won consumption can be acid inhibits the production. The oral disease is dental caries, gingivitis, oral, oral mucosal ulceration, EPA halitosis or an oral-care can be selected from any one. The galactose - L - 3, 6 - anhydro inhibit growth of oral bacteria, oral bacteria acids clause decayed tooth carbon won consumption and consequently inhibits the production activity disclosed. Thus, dental caries by oral bacteria, gingivitis, oral, oral mucosal ulceration, EPA halitosis or an oral-care such as prevention of oral cavity diseases, or a medicament for the treatment of, food, etc. can be use in oral hygiene. Figure 1 to 10 g/L of glucose carbon won, 3, 6 - anhydro - L - galactose in the medium in a medium for solid liquid xylitol and minimum minimum mu the [su[su] germ which burns indicating single carbon cancels the effects of growth are disclosed (substrate conditions: 10 g/L of glucose; 10 g/L of 3, 6 - anhydro - L - galactose; 10 g/L of xylitol. Dilution drainage: 10 times, 100 times, 1,000 times, 10,000 times, 100,000 times). Figure 2 to 10 g/L carbon won of glucose, galactose - L - 3, 6 - anhydro single carbon source in a medium liquid xylitol and minimum effect mu the [su[su] germ which burns growth are disclosed. Figure 3 shows a minimum of 3, 6 - anhydro - L - 10 g/L glucose in a medium containing galactose to acrylate won (A) (B) by inhibitory effects of xylitol on mu the [su[su] germ which burns livestock products are disclosed. Figure 4 shows a medium containing 10 g/L to 20 g/L glucose (A) acrylate won of xylitol (B) by the addition of 40 g/L and a minimum growth halitosis, livestock products remaining carbon source, and acid (lactic acid, formic acid, acetic acid) representing the result of generating analysis are disclosed. Figure 5 shows a minimum of 3, 6 - anhydro - L - 10 g/L glucose medium containing galactose to acrylate won (A) 0 g/L, 5 g/L (B), 10 g/L (C) obtained by adding mu the [su[su] germ which burns growth, livestock products remaining carbon source, acid (lactic acid, formic acid, acetic acid) representing the result of generating analysis are disclosed. The present inventors believe that agarose pre-treated, 3, 6 - anhydro simple process chain through three enzymatic hydrolysis using enzymes produced only galactose - L - 3, 6 - anhydro - L - galactose and galactose then was used for separation and purification by mu in the [su[su] germ which burns to carbon won. 3, 6 - anhydro - L - mu the [su[su] germ which burns growth inhibition acid generator are observed to have clause decayed tooth effect analysis for galactose, xylitol is regulated glucose carbon won comparison experiment was used. As a result, - L - 3, 6 - anhydro glucose galactose and xylitol and compared to colony forming as much as possible under the conditions, then the dilution source of carbon - L - 3, 6 - anhydro galactose conditions colony forming is uncertain. Also, galactose - L - 3, 6 - anhydro mu the [su[su] germ which burns not affecting the promotion of growth. The, 3, 6 - anhydro - L - and non-fermentable sugars as the xylitol mu in the [su[su] germ which burns galactose, galactose - L - 3, 6 - anhydro put into the xylitol much higher than the growth inhibition has been confirmed. Also, 3, 6 - anhydro - L - - L - 3, 6 - anhydro glucose galactose and mixed carbon won conditions in the galactose concentration inhibiting growth or cell growth mu the [su[su] germ which burns his high concentration does not take place. Xylitol concentration formed by inhibiting plant growth but significant cell growth was observed even mu the [su[su] germ which burns concentration. Also, mixing carbon won conditions, low concentration (5 g/L) of 3, 6 - anhydro mu the [su[su] germ which burns delay is the galactose - L - shaped, growth rate is reduced, and the concentration of resulting acid is reduced to confirm it is weakly inhibitory effects on the acid generator can be mu the [su[su] germ which burns cell growth, a high concentration (10 g/L) - L - 3, 6 - anhydro mu the [su[su] germ which burns growth pressure was not observed to have any acid generator of the galactose, 3, 6 - anhydro - L - 3, 6 - anhydro - L - galactose without changes in concentration of galactose mu the [su[su] germ which burns carbon won not capable using his car. While, 3, 6 - anhydro sugar xylitol known dental caries - L - 3, 6 - anhydro - L - 10 g/L of galactose concentrations much higher than 40 g/L under conditions of galactose as completely inhibiting mu the [su[su] germ which burns growth acid generator to prevent a support of the condition of the result. The lower parts of the xylitol is 3, 6 - anhydro - L - mu in the [su[su] germ which burns even for growth inhibitory effects on the acid generator that big galactose is much larger. Thus, the invention relates to a method for preventing or treating diseases galactose - L - 3, 6 - anhydro oral care compositions. Also, the invention relates to preparing a pharmaceutical composition for the prevention or treatment of oral cavity diseases for 3, 6 - anhydro - L - galactose of uses. The 3, 6 - anhydro - L - galactose carbohydrate component constituting the red algae biomass simple process representative of the stomach, Obtained through chemical synthesis; Which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase enzymes or prepared by reacting mixture; Which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct is sequentially hydrolase obtained by separation and purification reaction-product obtained by the reaction can be people. The temperature in the range of 40 to 150 °C agarose pretreatment of a weak acid in the agarose and reacting 6 be a time 5 minutes. The constituent esters when weak acetic acid and a residual product of agarose by the hyperpolarized gas can be minimize. The weak acid is acetic acid (Acetic acid), formic acid (Formic acid), succinic acid (Succinic acid), citric acid (Citric acid), malic acid (Malic acid), maleic acid (Maleic acid) or oxalic acid (Oxalic acid) can be used alone or in combination with at least one but like 2, the specially be limiting of the endured. After the separation of the steam and in view of the weak acid neutralizing weak salt 0. 5 to 60% (w/v) at a concentration of use now. More specifically 20 to a concentration of 40% (w/v) can be used. In order to detect a pre-generated after producing lofty houseper exo - (exo-a type) type of agarose raleigh direct decomposing activity and neopentylglycol with baby bio [su[su] reacting agar lot five [su[su] producing substrate. The direct method for the non-reducing end of β - 1, 4 bond lot-for the beta - galactosidase (beta-galactosidase agarolytic) step of inactivating the agar resolution processing with baby bio [su[su] galactose and 3, 6 - anhydro - L - producing neohesperidin dihydrochalcone, finally alpha - 3, 6 - anhydro - L - D - Neo using with baby bio [su[su]simple process chain Neo with baby bio [su[su] hydrolase galactose and galactose resolved into substrate. The enzyme reaction is 20 to 40 °C temperature in the range of 7 to about 30 can be soft. The enzymatic reaction more specifically described as follows. First, agar raleighlofty houseper chain by decomposing the agarose D - 3, 6 - anhydro - L - producing neohesperidin dihydrochalcone with baby bio [su[su] agarose degrading enzymes bind to beta - 1, 4 - galactose-glycoside of galactose and between enzymes (Aga50D ' referred to as) can be used. The agarose metalloprotease shows the SEQ ID NO: 1 amino acid sequences one or more permutations of the enzyme as well as a, defective, potential, such as agar raleighlofty house mutant proteins of added protein hydrolysis activity of enzyme are also included into the scope of the invention, preferably SEQ ID NO: 1 is the amino acid sequence at least 80% sequence identity, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, 96% or more, 97% or more, 98% or 99% amino acid sequence and at least one includes. The agarose metalloprotease shows the with Guus green onionhim only the [su[su] proteins ( The agarose metalloprotease shows the with Guus green onionhim only the [su[su] proteins ( When using recombinant techniques, used for recombinant protein expression and ease of conventional factors, e.g. antibiotic resistant genes, affinity column chromatography using the reporter protein or peptide can be used, as one skilled in the art relates these techniques is provided and becomes easily operable category corresponding with each other. Example agarose degrading enzymes edible strain, e.g. to yeast transform using cultures of transformed yeast supernatant can be formed to replace. More specific fabrication technique is a compensation public Internet route 2010 - 0040438 call (2010. 04. 20) can be referencing. The agar raleigh temperature in the range of 20 to 30 minutes 7 40 °C lofty house and agarose degrading enzyme reaction is in the can. More specifically, temperature in the range of 25 to 35 °C 1 to 4 can be soft. Next, a lot five [su[su]raleighlofty house hydrolysates with baby bio [su[su] and D - galactose hydrolyzing a direct direct the beta - galactosidase neohesperidin dihydrochalcone (beta-galactosidase agarolytic) is resolution direct (' The beta - galactosidase (beta-galactosidase agarolytic) the agar resolution is an enzyme belonging to GH family 2, beta - galactosidase activity when comparing identified belonging to other GH family 2, beta - galactosidase agar lot five [su[su] applied conventional reported D - galactose and neopentylglycol with baby bio [su[su] producing activity but, in Vibrio ( Beta - galactosidase (beta-galactosidase agarolytic) is the agar resolution is of immobilized enzyme as well as well as the area before and after the coding region of the respective coding segments associated to produce polypeptides sequences interposed between DNA segments, i.e.-encoding genes can be transcriptional and translational through. For example, SEQ ID NO: 2 but transcriptional and translational from the sequence a, the limited to are not correct. Also, one or more permutations of the enzymatic, defective, potential, such as mutant proteins of protein hydrolysis activity as agar lot five [su[su] added are also included into the scope of the invention enzyme, preferably SEQ ID NO: 2 is the amino acid sequence at least 80% sequence identity, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, 97% or more, and at least 99% amino acid sequence comprises at least 98%. The beta - galactosidase (beta-galactosidase agarolytic) into the agar resolution is Vibrio ( The beta - galactosidase (beta-galactosidase agarolytic) and direct the agar lot five [su[su] resolution temperature in the range of 30 to 40 °C the reactions of the 20 can be in the range from liver 7. More specifically 25 to 35 °C temperature in the range of 1 to 4 can be soft. The beta - galactosidase (beta-galactosidase agarolytic) the agar resolution method for the 30 to 40 °C at an in-lot is direct, about pH 5 to 9. 6 activity can exhibit. Finally, the neohesperidin dihydrochalcone with baby bio [su[su] - L - 3, 6 - anhydro D - galactose and galactose alpha - hydrolase (also referred to as' sdNABH ') can be resolved into Neo with baby bio [su[su] SEQ ID NO includes: one or more permutations of the enzyme as well as a 3 amino acid sequences, defective, potential, such as hydrolysis activity as Neo with baby bio [su[su] added mutant proteins of protein are also included into the scope of the invention enzyme, preferably SEQ ID NO: 4 is the amino acid sequence at least 80% sequence identity, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, 97% or more, 98% or 99% amino acid sequence and at least one includes. The Neo with baby bio [su[su] hydrolysis enzyme is alpha - with Guus green onionhim only the [su[su] proteins ( The Neo with baby bio [su[su] hydrolysis enzyme is alpha - with Guus green onionhim only the [su[su] proteins ( The temperature in the range of 20 to 40 °C reaction of the hydrolase alpha - Neo with baby bio [su[su] andwith baby bio [su[su] neopentylglycol 30 minutes 7 can be soft. More specifically 25 to 35 °C temperature in the range of 1 to 4 can be soft. The Neo with baby bio [su[su] degradation product in order to use chromatography comprises silica gel chromatography and gel permeation chromatography in high purity of approximately 95% gel P2 chromatography biometric sequentially purifying a galactose - L - 3, 6 - anhydro can be. "Protein" herein "polypeptides" are used interchangeably herein and each other in. In the present invention another polypeptide sequence (e.g., 80%, 85%, 90%, 95%, or 99%) is specified relative to the ratio of frames are having sequence identity, when aligning the two sequences, the sequence of amino acid residues compared to the ratio to relate to big. The alignment and the percentage homology or identity, any appropriate software programs known in the art, e.g. document [Current Protocols in Molecular Biology (F. M. Ausubel (eds) such as 1987 Supplement 30 Section 7. 7. 18)] a can be determined using those. In a preferred program include, GCG Pileup program, FASTA (Pearson 1988 such as In the present invention cells, nucleic acid, protein or vector when use in conjunction with the terms "recombinant", the cells, nucleic acid, protein or vector is the introduction of heterologous nucleic acids or proteins which have been modified by the modification of the shaft or nucleic acid or protein, or cells derived from cells thus indicating other. I.e., e.g., recombinant cells expressing shaft (non-(non) recombinant) form not found within the cells expressing the gene or, alternatively expression expressed or not expressed any abnormal shaft expressing the gene substrate. Single or double-stranded DNA "nucleic acid" herein, RNA, and a chemical modification of the P19. ".. ". "". "Nucleic acid" and "polynucleotide" can be used in interchangeable herein. Because dielectric when a password to the amplifier, one or more codons for encoding specific amino acids can be used, the invention relates to polynucleotides encoding the amino acid sequence to the P19. The terms "introducing" a nucleic acid sequence inserted into cells "transfection (transfection)", or "transgenic" or "transduction (transduction)" which means, eukaryotic or prokaryotic is included in the mention of integration of nucleic acid sequences into cells, the cell (e.g., chromosome, plasmid, plastid, or mitochondria DNA) said nucleic acid sequences is integrated into the genome of, or autonomous replicon is transformed into, or temporal expression of with each other. The galactose - L - 3, 6 - anhydro product produced after of enzymatic reactions in silica gel chromatography for separation and purification only adsorbent chromatography is gel permeation chromatography using biometric gel P2 chromatography, can the dose through the GC/MS analysis. Pharmaceutical compositions of the present invention can further include a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier commonly used in medicine and carrier and vehicle, ion exchange resin, alumina, aluminum stearate, lecithin, serum protein (e.g., human serum albumin), buffer material (e.g., various phosphate, glycine, sorbitol having a stabilized, potassium polysorbates, saturated vegetable fatty acid partial triglyceride mixture), water, salt or electrolyte (e.g., protamine sulfate, phosphate hydrogen natrium, hydrogen [kham[kham] loom phosphate, sodium chloride and zinc salt), colloid characteristic silica, magnesium tree silicate, polyvinyl pyrrolidone, cellulosic based substrate, polyethylene glycol, sodium carboxy methylcellulose, polyarylate, wax, including but not limited to polyethylene glycol or wool center. Also, pharmaceutical compositions of the present invention components in addition to the lubricant, wetting agent, emulsifier, suspending agent, or can be further include preservatives. As one aspect, the pharmaceutical compositions according to the invention suitable for parental administration or oral administration can be formulated in various dosage used. The formulation for oral administration for unrestrictedly example, trough height system (troches), the percentage (lozenge), tablet, aqueous dispersion, oily suspension, preparing powder, granules, emulsion, hard capsule, soft capsule, syrup or the like l [lik[lik] hour [lu[lu] system is cited. For pharmaceutical compositions of the present invention formulated for oral administration, lactose, food proteins, sorbitol, mannitol, starch, amylopectin (Amylopectin), cellulose (Cellulose) gum or gelatin (Gelatin) such as binder; d calcium phosphate (Dicalcium phosphate) such as excipient; coloring agents such as corn starch or collapsible first; (Magnesium stearate) magnesium stearic acid, calcium stearate (Calcium stearate), wax or polyethylene glycol such as box fumaric acid sodium (Sodium stearyl fumarate) (Polyethylene glycol wax) using low-temperature fluidity can be, sweetener, aromatic, syrup or the like can be used. In addition separating liquid carrier material such as the aforementioned further capsule a formula like fat can be additionally used. Said parenteral formulation for unrestrictedly example, cap, left system, powder for respiratory suction, first spray aerosol, oral spreading now, oral detergent, toothpaste first, ointment, for application to the powder, oil, cream or the like is cited. For pharmaceutical compositions of the present invention formulated for parenteral administration, sterile aqueous solution, non-aqueous solvent, suspension, emulsion, freeze-dried preparation, can be use for topical application, the non-aqueous solvent, suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, such as injectable can be the [ley[ley] which comes the [thu[thu] and ethyl ester is used as the alkali. Also, more specifically when a pharmaceutical composition of the present invention formulated cap, stabilizer or buffer composition of the present invention solution or suspension in water with mixing for making ampoule (ampoule) or vial (vial) of unit dosage can be formulated for. Also, when formulated with aerosol pharmaceutical compositions of the present invention, moisture sulphonic concentrate or wet powder dispersed with corresponding additives can be blended to propulsion and the like. Also, pharmaceutical compositions of the present invention ointment, cream or the like when formulated, animal oil, vegetable oil, wax, paraffin, starch, coating space [thu[thu], cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide or the like can be formulated using carrier. Pharmaceutical compositions of the present invention pharmaceutical, the pharmaceutical composition comprising an effective dose formulated method, administration method, administration can be by time and/or routes information to, the pharmaceutical composition administered in a central reaction types and the extent, of an individual subject is type, age, weight, general health state, the symptoms of disease or degree, sex, dietary, a printed wiring board, simultaneous or other objects together the use of other composition as the corresponding time in medicine information to a variety factor and can be well-known like factor according, having knowledge of the art user typically encountered in the desired manner are effective in the treatment dose can be prescribed. Pharmaceutical compositions of the present invention can be by administering a single administration per day 1, many times made in can be administered. The second dosage is not the defining any way the scope of this invention. Pharmaceutical compositions of the present invention routes and administration can be independent of each scheme is, in correspondingly limited to way, can reach the desired provided as the pharmaceutical composition according any of routes and administration can be. The pharmaceutical compositions include oral administration or parenteral administration can be administering manner. Said parenteral methods of administration include, e.g. intravenous administration, administered either intraperitoneally, intramuscular administration, subcutaneous administration or transdermal administration can be for example, a phrase disease the composition or spray, but are not limited to suction also using not substrate. Pharmaceutical compositions of the present invention can be administered preferably orally administered or increase. The terms to be used herein, "prevention" RM, a subject in need thereof a pharmaceutical composition of the present invention inhibiting or retarding the onset of oral disease's big. The terms to be used herein, "treatment" implies, a subject in need thereof a pharmaceutical composition of the present invention to advantageously to oral diseases or quick-loop's big. In the present invention the oral disease is oral diseases including both generated and regardless if the instant concept and, for example, Streptococcus mutans ( The invention also relates to a pharmaceutical composition for the prevention or treatment of oral administering to a subject a method of preventing or treating oral diseases. The terms to be used herein, "individual" includes grip, livestock, means all animals including human mammals other. Preventives or oral of the present invention in therapeutic methods, the pharmaceutical composition dosage, routes, such as administering a description is, within the scope of the present invention taught that the are the same as. The invention also relates to galactose - L - 3, 6 - anhydro of oral cavity diseases for treatment or prevention of an oral composition comprising are disclosed. In the present invention, the 3, 6 - anhydro - L - galactose, oral disease and prevention description is, within the scope of the present invention taught that the are the same as. In the present invention the oral care compositions further comprise all types and formulations can be used for sanitary. The an oral composition examples but not limited to, toothpaste, mouthwash, oral spray, oral ointments, gum or the like is cited. Of the present invention an oral composition suitable for administration by oral administration or parenteral formulations can be formulated in various used, within the scope of the present invention equipped description is the same as taught that the. The terms are used in the invention, "improving" is remedied that a parameter, e.g. symptom's at least reducing degree of big. The invention also relates to a food composition for preventing or ameliorating diseases galactose - L - 3, 6 - anhydro oral care are disclosed. In the present invention, 3, 6 - anhydro - L - galactose, oral, prevention, a description is improved by, within the scope of the present invention taught that the are the same as. Correspondingly limited to food composition of the present invention, comprise a health food composition. Terms, "health food" RM, the galactose - L - 3, 6 - anhydro beverage, type, flavoring agents, gum, either adding like confectionery material, encapsulated, powdered, suspension or the like food manufacturing, rpm when specific health facility means other. Health food containing low food additive functions of the present invention, the composition can be used with either adding other as food or food ingredients, can be suitable for use according to conventional methods. Correspondingly limited to the kind of the food, food in conventional meaning including both substrate. The substance can be added for unrestrictedly food example meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, if, other noodles, gum type, ice cream acid a dairy product, various soup, beverage, difference, is suitable, alcoholic drinks and vitamin complex or the like is cited. When beverage composition which health food composition of the present invention, the beverage with various flavors or natural carbohydrate or the like as conventional can be additional active ingredient. The natural carbohydrate for unrestrictedly for example glucose, such as oligosaccharides monosaccharide; liver, a disaccharide such as sucrose; dextrin, cyclodextrin such as natural sweetener; saccharin, such as oh [su[su] group [lu[lu] with burning, synthetic sweetener or the like is cited. Additional said added the amounts of ingredients can be properly selected by one skilled. In addition to the health food composition includes nutritional agents of the present invention, vitamin, electrolyte, flavorants, colorants, [pheyk[pheyk] The [thu[thu] it buys and salts thereof, alginic acid and salts thereof, organic acid, protective colloidal thickener, pH modulators, stabilizer, preservative, glycerin, alcohol, carbonic acid agent can be used in carbonated beverages and the like. In addition to this mixture nutraceutical composition comprises natural fruit juice, fruit beverage or vegetable drinks containing pulp for the manufacture can be. These components are independently used or 2 or more can be used in combination. The ratio of the additive can be appropriately selected by one skilled. Below, embodiments according to the present invention through transmissions take but which utilizes the present invention, the scope of this invention R1 is limited by the presented embodiment are not correct. 1><embodiments pretreatment of agarose 3N to 7% (w/v) agarose concentration of acetic acid in 10 minutes after melt-so using microwave digester 130 °C reacts with 1. 5L into ethanol by washing twice remaining 94% of acetic acid and hyperpolarized seafood the summit. Reaction-product 24 hours freeze-dried powder state of agar raleighlofty house stingy. By hydrolysis of 3, 6 - anhydro lofty house<embodiments raleigh enzymatic resolution of production of galactose - L - 2>agar Embodiments 1 acid hydrolysate produced from a galactose and 3, 6 - anhydro D - simple process chain (agar raleighlofty house) - L - (exo-a type) of beta - agar it is a sacrifice exo - type for galactose resolved into Aga50D (2010 - 0040438 a compensation public Internet route call, 2010. 04. 20 reference) on has been reacted, and neopentylglycol diazonaphthoquinone agar lot five [su[su]with baby bio [su[su] been generated. Aga50D five [su[su] substances while using non-reduction of binding at the end of the lot of inactivating β 1 - 4 after agar Neo with baby bio [su[su] D - 3, 6 - anhydro - L - for producing simple process chain from galactose and galactose The three recombinant enzyme is e. coli ( Silica gel chromatography using 3><embodiments bio-gel P2 chromatography separation and purification Embodiments 2 - L - 3, 6 - anhydro produced in reaction product for chromatography separation and purification only galactose in implementation. Reaction-product adsorbed onto the powder in the form of a slotted 2000 after which the adsorption chromatography is silica gel chromatography sample implementation. A furnace is chloroform: methanol: water ratio of 0.50 to each 78:20:2 (v/v/v) selected from the entire mid been 4L the volume of solvent. A sample of 20 ml total volume fraction of 3, 6 - anhydro - L - 200 fraction after a pulse is then subject to analysis TLC galactose fraction was collected removing organic solvent with vacuum condenser rotation. 4>GC/MS<embodiments by analyzing 3, 6 - anhydro - L - galactose qualitative and quantitative Embodiments 3 - L - 3, 6 - anhydro-purity produced by galactose was then subject to analysis by GC/MS quantifying. GC/MS derivatized process for analysis as follows. Purified samples of 4% (w/v) concentration of 10 micro l drying speed bag after melting O - methyl hydroxylamine hydrochloride (O a-methylhydroxylamine hydrochloride in pyridine) pyridine in 30 °C and 120 minutes with respect to the placed in the reaction. L and 45 of micro 5><embodiments cell culture conditions The experiments use in Streptococcus mutans strains ( 6>mu the [su[su] germ which burns<embodiments single carbon won conditions their growth inhibitory effect 10 g/L 3, 6 - anhydro mu the [su[su] germ which burns growth inhibitory effects on the single carbon won conditions for viewing of - L - galactose, glucose, xylitol solid medium respectively him as mu the [su[su] germ which burns minimum minimum liquid medium. A 2 mm potassium phosphate buffer 10 times before (pre-a culture) culture mu the [su[su] germ which burns, 102 Times, 103 Times, 104 Times, 105 Solid medium spots (spotting) 30 and dilution times him as time. Also as shown in the 1, 3, 6 - anhydro glucose under conditions as much as possible - L - galactose and xylitol compared to colony forming been. Particularly in the case of 10 - L - 3, 6 - anhydro galactose4 Times, 105 Not observed little colony dilution times in various conditions. Also, 10 g/L of each carbon won (3, 6 - anhydro - L - galactose, glucose, xylitol) by culturing in a medium a liquid minimum mu the [su[su] germ which burns cells promotes cell growth inhibition effect observed. 5 embodiments of method 600 nm at a wavelength of 5 to 35 hours the (main-a culture) culture of mesenchymal cell growth by measuring absorbance measured degree of every predetermined time. Also as shown in the variation 2, glucose concentration (stationary phase) after drying time to the manhood of quiescent mu the [su[su] germ which burns under the contact portions (dry cell weight, DCW) 20 is 4. 05 g/L concentration thereof measured too soon and, in the case of drying process to xylitol significantly reduced amount 1. 46 g/L concentration thereof measured have been, in the case of galactose - L - 3, 6 - anhydro mu the [su[su] germ which burns growth is not observed at all. The, 3, 6 - anhydro - L - and non-fermentable sugars as the xylitol mu in the [su[su] germ which burns galactose, galactose - L - 3, 6 - anhydro put into the xylitol much higher than the growth inhibition has been confirmed. 7>growth inhibitory effect mixing carbon won conditions mu the [su[su] germ which burns<embodiments 5 - L - 3, 6 - anhydro glucose concentration of 10 g/L with the method of embodiments by galactose or xylitol 96 - well plate in a medium comprising liquid minimum 200 micro l small stores time measuring absorbance at a wavelength of 600 nm mu the [su[su] germ which burns culturing growing observed inhibitory effects. 3, 6 - anhydro - L - 20 g/L in concentration of 0 g/L galactose, xylitol 0 g/L concentration was 40 g/L in between each. Also as shown in the 3, 1. 3 and 2. 5 g/L concentration of galactose - L - 3, 6 - anhydro mu the [su[su] germ which burns growth large changes in service has, from 5 and 10 g/L concentration observed significant cell growth inhibitory effects on the transparent conductive layer, concentration of 20 g/L in cell growth did not occur. In the case of processing of xylitol concentration increase as much as possible but xylitol mu the [su[su] germ which burns growth, a significantly higher concentration of 40 g/L concentrations even been significant cell growth is observed. The, - L - 3, 6 - anhydro cells promotes cell growth inhibition effect is greater the lower parts of the xylitol even galactose that result therefrom. 8><halitosis growth inhibitory effects on the acid generator embodiments mixed carbon won conditions 3, 6 - anhydro - L - galactose or xylitol mu the [su[su] germ which burns growth acid generator in order to identify embodiments 5 glucose 10 g/L of an influence on the process of 0, 5, 3, 6 - anhydro - L - 10 g/L of galactose or 20, 40 g/L of the storehouse mu the [su[su] germ which burns 35 5 5 ml liquid medium culturing each including a minimum time every predetermined time absorbance using cell growth, extracellular matrix concentration using HPLC concentration acid generator therefrom. Adding glucose conditions only voice controls, xylitol was set added glucose regulated positive conditions. Analysis and using the columns Aminex HPX provided 87H, mobile on 0. 01N 65 °C 0 in sulfuric acid. At a rate of 5 ml/min flow me. As shown in the variation also 4A, contain only carbon won under conditions of glucose 3 construction process amount. 34 g/L have been measured, nasal voice market rate 0. 086h-1 Min. The lactic acid concentration of 30 time has been consumed both only glucose 5. 24 g/L has been measured. In addition the concentration of formic acid with acetic acid generated a small amount each 0. 82, 0. 71 g/L min. 10 g/L to 5 g/L of glucose galactose of 3, 6 - anhydro - L - comprising a reduced concentration of not but retarder (lag phase) mu the [su[su] germ which burns under the final dry contact portions of a and c becomes long, nasal voice market speed value 0. 075h-1 Reducing the concentration of the resulting acid with respect to cells via growth inhibitory effects on the acid generator that is weakly reduced result has been confirmed (also 4B). 10 g/L to 10 g/L of glucose galactose - L - 3, 6 - anhydro of growth or not observed to have acid generator comprising mu the [su[su] germ which burns under his. Two conditions which change the concentration of 3, 6 - anhydro - L - room also both galactose, galactose - L - 3, 6 - anhydro mu the [su[su] germ which burns through carbon won use substantially cannot be point (also 4C) has been confirmed. Also, 10 g/L to 20 g/L of glucose comprising xylitol of final dry under positive controls as contact portions is 1. 42 g/L mu the [su[su] germ which burns growth inhibition occurs but nasal voice market speed value is to 0. 087h-1 Voice controls of 0. 086h-1 When change in comparison with the processor. Total glucose 5. 28 g/L is expended too soon, the concentration of the lactic acid with acetic acid generated each 3. 67, 0. 55 g/L (also 5A) has been reduced relative to controls the voice. 10 g/L to 20 g/L under the high concentration of 40 g/L of glucose comprising xylitol (lag phase) is an elongated sources of xylitol relative to delay and to selectively, concentration of glucose consumed 5. 42 g/L has been to similarly measurement. Each glucose consumption been created due to the concentration of the lactic acid with acetic acid 3. 67, 0. 55 g/L (also 5B) been is measured. Also, a malt mu the [su[su] germ which burnsmu in the [su[su] germ which burns through at the point of of xylitol concentration kept at a constant which for non-fermentation properties of xylitol has been confirmed. 3, 6 - anhydro sugar through known dental caries results xylitol - L - 3, 6 - anhydro - L - 10 g/L of galactose concentrations much higher than 40 g/L under conditions of growth inhibiting mu the [su[su] germ which burns galactose as completely acid generator to prevent a support of the condition of the result. The lower parts of the xylitol is 3, 6 - anhydro - L - mu in the [su[su] germ which burns even for growth inhibitory effects on the acid generator that big galactose is much larger. The present invention relates to an anticariogenic use of 3,6-anhydro-L-galactose. The 3,6-anhydro-L-galactose inhibits growth of oral bacteria and has an anticariogenic activity of inhibiting formation of acid by consumption of carbon source of oral bacteria, thereby being used for medicines, foods, oral sanitizers, etc. for preventing, alleviating or treating oral diseases such as dental caries, gingivitis, periodontitis, mucosal ulcer in mouth, bad breath, xerostomia, etc. by oral bacteria. COPYRIGHT KIPO 2017 3, 6 - anhydro - L - galactose (3, 6 a-anhydro-a L-a galactose) comprising oral pharmaceutical compositions for preventing or treating. According to Claim 1, 3, 6 - anhydro - L - and galactose it was preprocessed agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase enzymes or mixture, which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase obtained by separation and purification reaction-product sequentially obtained by the reaction substrate is, for prevention or treatment of oral pharmaceutical compositions. According to Claim 2, a temperature in the range of 40 to 150 °C 5 minutes 6 hours and agarose pretreatment weak reaction to the reaction solution, oral pharmaceutical compositions for preventing or treating. According to Claim 2, agarose metalloprotease shows the SEQ ID NO: 1 amino acid sequences represented by a, oral pharmaceutical compositions for preventing or treating. According to Claim 2, beta - galactosidase (beta-galactosidase agarolytic) is the resolution direct SEQ ID NO: a 2 amino acid sequences can be used, for prevention or treatment of oral pharmaceutical compositions. According to Claim 2, alpha - Neo with baby bio [su[su] hydrolysis enzyme SEQ ID NO: a 3 amino acid sequences can be used, for prevention or treatment of oral pharmaceutical compositions. According to Claim 1, oral dental caries, gingivitis, oral, oral mucosal ulceration, which is one selected from EPA or an oral-care of halitosis, oral pharmaceutical compositions for preventing or treating. 3, 6 - anhydro - L - galactose (3, 6 a-anhydro-a L-a galactose) comprising of oral cavity diseases for treatment or prevention of an oral composition. According to Claim 8, 3, 6 - anhydro - L - and galactose it was preprocessed agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase enzymes or mixture, which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase obtained by separation and purification reaction-product sequentially obtained by the reaction substrate is, of oral cavity diseases for treatment or prevention of an oral composition. According to Claim 9, a temperature in the range of 40 to 150 °C 5 minutes 6 hours and agarose pretreatment weak reaction to the reaction solution, of oral cavity diseases for treatment or prevention of an oral composition. According to Claim 9, agarose metalloprotease shows the SEQ ID NO: 1 amino acid sequences represented by a, of oral cavity diseases for treatment or prevention of an oral composition. According to Claim 9, beta - galactosidase (beta-galactosidase agarolytic) is the resolution direct SEQ ID NO: 2 amino acid sequences represented by a, of oral cavity diseases for treatment or prevention of an oral composition. According to Claim 9, alpha - Neo with baby bio [su[su] hydrolysis enzyme SEQ ID NO: 3 amino acid sequences represented by a, of oral cavity diseases for treatment or prevention of an oral composition. 3, 6 - anhydro - L - galactose (3, 6 a-anhydro-a L-a galactose) comprising teeth for preventing or ameliorating food composition. According to Claim 14, 3, 6 - anhydro - L - and galactose it was preprocessed agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase enzymes or mixture, which has been pretreated with agarose, agarose degrading enzymes, beta - galactosidase (beta-galactosidase agarolytic) and alpha - Neo with baby bio [su[su] resolution direct the hydrolase obtained by separation and purification reaction-product sequentially obtained by the reaction substrate is, for treatment or prevention of oral food composition. According to Claim 15, a temperature in the range of 40 to 150 °C 5 minutes 6 hours and agarose pretreatment weak reaction to the reaction solution, oral food composition for preventing or ameliorating. According to Claim 15, agarose metalloprotease shows the SEQ ID NO: 1 amino acid sequences represented by a, oral food composition for preventing or ameliorating. According to Claim 15, beta - galactosidase (beta-galactosidase agarolytic) is the resolution direct SEQ ID NO: 2 amino acid sequences represented by a, oral food composition for preventing or ameliorating. According to Claim 15, alpha - Neo with baby bio [su[su] hydrolysis enzyme SEQ ID NO: a 3 amino acid sequences can be used, for treatment or prevention of oral food composition.
